

Xenia Venture Capital's Xenolith raises more than NIS 1 million from Europe's Rocamed

Xenolith has FDA and CE approval for its proprietary ureteroscopic filter for the prevention of the migration of stone fragments to the kidneys

Tel Aviv, Israel, 17 July 2014 - Xenia Venture Capital Ltd. (TASE: XENA), a public investment company specializing in medical devices and IT, announces that portfolio company Xenolith Ltd. (in which it has an 18% holding) has signed a distribution agreement with Europe-based Rocamed, which includes an investment by Rocamed of NIS 1.03 million (USD 300,000) in Xenolith.

Xenolith is an Israeli medical device company that is engaged in the development of a proprietary ureteroscopic filter for the prevention of the migration of stone fragments to the kidneys, following a laser procedure for disintegrating kidney- or bladder stones. The product has CE certification for marketing in Europe. Rocamed is a leading European company specializing in the manufacture and marketing of endo-urological products. It operates in most European countries, South America, the Far East, and the Arab world.

Under the terms of the agreement, Rocamed's USD 300,000 investment in Xenolith will give it an 18% stake in the company. Under the agreement, Rocamed will be the exclusive distributor of Xenolith's filter product in Europe, South America and Asia.

According to Anat Segal, CEO of Xenia Venture Capital: "The capital raised by Xenolith, together with the distribution agreement with Rocamed, emphasizes the faith in the product by one of the specialist distributors of ureteroscopic products. Xenolith has substantial economic potential, based on the need for an effective solution for a steadily growing market. We continue to strive to create collaborations for our portfolio companies with multinationals to develop, market, and invest in the commercialization of the portfolio companies' innovative technologies and to create value for our shareholders."

Xenolith was founded at Xenia in 2010 in collaboration with US-based Virginia Life Science Investments LLC (VSLI) and leading investors in other Xenia portfolio companies specializing in urological solutions. Xenolith has FDA approval for marketing in the US and CE approval for marketing in Europe. It initiated US sales this year.

According to Shaul Shohat, founder and CEO of Xenolith: "Xenolith's product is an innovative product that meets a real need, and its addition to Rocamed's products catalogue is an important milestone for us, providing us with greater exposure to additional strategic parties. As a result, our product is at the forefront of Rocamed's marketing activity."

Kidney stones affect 5-7% of women and 10-12% of men. Five million cases of kidney stones are diagnosed each year.

Video clip featuring Xenolith's product:

[Xenolith - YouTube](#)

About Xenia Venture Capital:

Xenia Venture Capital is a public Israeli investment company specializing in medical devices and IT companies. It has 12 active portfolio companies in various stages of development in the internet and media, communications, medical devices, and pharmaceutical fields. Xenia's portfolio companies have unique technologies with deep intellectual properties, most of which have developed unique products sold in global markets, forged strategic partnerships with leading companies in their fields, including marketing, distribution, and well as direct investment agreements. Xenia's portfolio companies have so far raised more than NIS 280 million in aggregate, from leading investors in Israel and abroad, and are valued (in accordance with latest funding rounds) at more than NIS 580 million. Xenia has made two exits so far -- one in 2012 and the other in 2013, first -- the sale of Arcos (in which it held 35% at closing) to a Canadian Company, for NIS 100 million, and the second -- the sale of its holdings in SAManage. The Company has forged strategic partnerships with leading investment firms and companies both in Israel and around the world. Its advisory committee includes key figures in its areas of expertise, and its shareholders include industry and capital market leaders from Israel. Xenia has cumulative holdings (its share) valued at NIS 23.7 million, according to its portfolio companies' latest rounds. www.xenia.co.il

Xenia's prominent portfolio companies:

Superfish -- a visual web-based search engine with over 80 million users.

Polypid -- a platform for local, delayed and controlled release of a range of drugs in a wide variety of applications, including orthopedics, dental implants, bone cancer, etc.

Playcast -- technological platform for cloud-based games. Has cooperation agreements for media content sharing with the world's leading brands, such as: Sega, Atari, Capcom, and Disney.

Saguna -- a software offering mobile caching to relieve loads in mobile networks due to the increasing volume of video and image content in these networks.

Ortho-Space -- an expendable balloon implant which is intended to treat patients suffering from shoulder pain as a result of the Rotator Cuff Syndrome. ArthroCare has made a strategic investment in the Company.